Design, synthesis and molecular modeling study of acylated 1,2,4-triazole-3-acetates with potential anti-inflammatory activity

European Journal of Medicinal Chemistry

Volumn 44, Issue 1, 2009, Pages 117-123

  Abdel Megeed, Ashraf M ^a   Abdel Rahman, Hamdy M ^a   Alkaramany, Gamal Eldien S ^a   El Gendy, Mahmoud A ^a  

^a Assiut University   (Egypt)

Author keywords

1,2,4 Triazole; Acylation; Anti inflammatory; COX 2; Docking; Heteroarylacetic acids

Indexed keywords

1,2,4 TRIAZOLE 3 ACETATE DERIVATIVE; ANTIINFLAMMATORY AGENT; ETHYL 1 (4 BROMOBENZOYL) 5 AMINO 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 1 (4 CHLOROBENZOYL) 5 AMINO 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 1 (4 METHOXYBENZOYL) 5 AMINO 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 1 (4 NITROBENZOYL) 5 AMINO 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 1 BENZOYL 5 AMINO 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 5 (4 BROMOBENZAMIDO) 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 5 (4 CHLOROBENZAMIDO) 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 5 (4 METHOXYBENZAMIDO) 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 5 (4 NITROBENZAMIDO) 1H 1,2,4 TRIAZOLE 3 ACETATE; ETHYL 5 BENZAMIDO 1H 1,2,4 TRIAZOLE 3 ACETATE; INDOMETACIN; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; INFLAMMATION; LD 50; MALE; MOLECULAR MODEL; NONHUMAN; PAW EDEMA; RAT; STOMACH ULCER; STRUCTURE ANALYSIS; ULCEROGENESIS;

ACETATES; ACYLATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG DESIGN; DRUG TOXICITY; EDEMA; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RATS; STOMACH ULCER; TRIAZOLES;

EID: 57949107840     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2008.03.017     Document Type: Article

References (23)

1. Bahekar S.S., and Shinde D.B. Bioorg. Med. Chem. Lett. 14 (2004) 1733-1736
2. Caliendo G., Cirino G., Greco G., Novellino E., Perissutti E., Pinto A., Santagada V., Silipo C., and Sorrentino L. Eur. J. Med. Chem. 29 (1994) 381-388
3. Knaus E.E., and Kumar P. Eur. J. Med. Chem. 28 (1993) 881-885
4. Daidone G., Maggio B., Plescia S., Raffa D., Schillaci D., Migliara O., Caruso A., Cutuli V.M.C., and Amico-Roxas M. Il Farmaco 53 (1998) 350-356
5. Kalgutkar S., Marnett A.B., Crews B.C., Remmel R.P., and Marnett L.J. J. Med. Chem. 43 (2000) 2860-2870
6. Dannhardt G., and Laufer S. Curr. Med. Chem. 7 (2000) 1101-1112
7. Galanakis D., Kourounakis A.P., Tsiakitzis K.C., Doulgkeris C., Rekka E.A., Gavalas A., Kravaritou C., Charitos C., and Kourounakis P.N. Bioorg. Med. Chem. Lett. 14 (2004) 3639-3643
8. Sung K., and Lee A.R. J. Heterocycl. Chem. 29 (1992) 1101-1109
9. Mullican M.D., Wilson M.W., Connor D.T., Kostlan C.R., Schrier D.J., and Dyer R.D. J. Med. Chem. 36 (1993) 1090-1099
10. Boschelli D.H., Connor D.T., Bornemeier D.A., Dyer R.D., Kennedy J.A., Kuipers P.J., Okonkwo G.C., Schrier D.J., and Wright C.D. J. Med. Chem. 36 (1993) 1802-1810
11. Czollner L., Szilagyi G., Lango J., and Janaky J. Arch. Pharm. (Weinheim) 323 (1990) 225-227
12. Palaska E., Sahin G., Kelicen P., Durlu N.T., and Altinok G. Il Farmaco 57 (2002) 101-107
13. Boyer J.H. In: Elderfield R.C. (Ed). Heterocyclic Compounds (1961), Wiley-VCH, New York, USA 425-460
14. Kofman T.P., Uvarova T.A., and Kartseva G.Y. Russ. J. Org. Chem. 31 (1995) 240-244
15. Peet N.P., Baugh L.E., Sunder S., Lewis J.E., Matthews E.H., Olberding E.L., and Shah D.N. J. Med. Chem. 29 (1986) 2403-2409
16. Dzygiel A., Rzeszotarska B., Masiukiewicz E., Cmoch P., and Kamienski B. Chem. Pharm. Bull. 52 (2004) 192-198
17. Fidler Z.N., Shibanova E.F., Makerov P.V., Kalikhman I.D., Shulunova A.M., Sarapulova G.I., Klyba L.V., Vitkovskii V.Y., Chipanina N.N., Lopyrev V.A., and Voronkov M.G. Chem. Heterocycl. Compd. 16 (1980) 1079-1083
18. Reiter J., Pongo L., and Dvortsak P. J. Heterocycl. Chem. 24 (1987) 127-142
19. Kasahara Y., Hikino H., Tsurufuji S., Watanabe M., and Ohuhi K. Planta Med. 51 (1985) 325-331
20. Ikuta H., Shirota H., Kobayashi S., Yamagishi Y., Yamada K., Yamatsu I., and Katayama K. J. Med. Chem. 30 (1987) 1995-1998
21. Bekhit A.A., and Fahmy H.T. Arch. Pharm. Pharm. Med. Chem. 336 (2003) 111-118
22. Molecular Operating Environment (MOE), Version 2005.06 (2005), Chemical Computing Group, Inc., Montreal, Quebec, Canada.
23. Pouplana R., Lozano J.J., and Ruiz J. J. Mol. Graphics Model. 20 (2002) 329-343